Evaluation of late clinical events after drug-eluting versus bare-metal stents in patients at risk: BAsel Stent Kosten Effektivitats Trial - PROspective Validation Examination

Trial Profile

Evaluation of late clinical events after drug-eluting versus bare-metal stents in patients at risk: BAsel Stent Kosten Effektivitats Trial - PROspective Validation Examination

Completed
Phase of Trial: Phase IV

Latest Information Update: 18 Dec 2015

At a glance

  • Drugs Everolimus (Primary) ; Sirolimus (Primary)
  • Indications Coronary artery disease; Coronary artery restenosis
  • Focus Therapeutic Use
  • Acronyms BASKET-PROVE
  • Most Recent Events

    • 17 Jul 2015 Results of pre-specified subgroup analysis (n = 405/2314; aged greater than or equal to 75 years) published in the American Heart Journal.
    • 31 Aug 2011 Results of a priori-planned analysis of the effects of renal function on treatment outcomes presented at the ESC Congress 2011: Annual Congress of the European Society of Cardiology.
    • 31 Aug 2011 Results of a priori-planned gender-specific analysis presented at the ESC Congress 2011: Annual Congress of the European Society of Cardiology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top